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1. Introduction
Immunohistochemical (ihc) stains are widely used for diagnosis of tumors. In this chapter we
present modern immunohistochemical stains for diagnosing those tumors that cannot be
evaluated via common or routine stains such as hematoxylin and eosin.
2. Epithelial tumors
Squamous cell carcinoma (SCC) and malignant melanoma are common epithelial lesions that
require IHC.
2.1. Squamous cell carcinoma
2.1.1. Definition
SCC is a malignant neoplasm arising from the squamous epithelium of the oral cavity most
commonly from the lip, then tongue, floor of mouth, gingiva, palate, and buccal mucosa.
Premalignant changes present as white (leukoplakia) or red (erythroplakia) mucosal patches.
2.1.2. Immunohistochemical stains
Squamous carcinomas are nearly always positive for CK.
• Common CK expression in squamous carcinomas includes AE1/AE3 and CKs 5, 5/6, 14,
and 17.
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• Nuclear p63 expression is common in squamous cell carcinomas but is not specific
• Cytokeratin stains may help detect subtle metastatic foci especially in post-treatment lymph
nodes (Figure 1).
• Over expression of p53 may be linked to response to radiation and/or chemotherapy
• p16 positive: strong and diffuse nuclear and cytoplasmic expression in oropharyngeal
carcinoma (HPV associated). [1-5]
a)  b) 
 
Figure 1. a) Squamous cell carcinoma (H&E). b) Cytokeratin stains in SCC.
2.2. Mucosal melanoma
2.2.1. Definition
Malignant mucosal melanoma (MMM) is a neural crest–derived neoplasm originating from
melanocytes and demonstrating melanocytic differentiation.
2.2.2. Immunohistochemical stains
S100 protein, Melan A, HMB45, tyrosinase, vimentin are positive, Keratin and muscle markers
are negative (Figure 2). [6-13]
a) b)
Figure 2. a) Mucosal melanoma (H&E) b) IHC staining for HMB-45
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3. Salivary gland tumors
The common salivary gland tumors needing IHC are:
• PLEOMORPHIC ADENOMA
• BASAL CELL ADENOMA
• CANALICULAR ADENOMA
• ONCOCYTOMA
• PAPILLARY CYSTADENOMA LYMPHOMATOSUM (WARTHIN TUMOR(
• SEBACEOUS ADENOMA/LYMPHADENOMA
• MUCOEPIDERMOID CARCINOMA
• ADENOID CYSTIC CARCINOMA
• POLYMORPHOUS LOW-GRADE ADENOCARCINOMA
• EPITHELIAL-MYOEPITHELIAL CARCINOMA
• CLEAR CELL CARCINOMA
• ACINIC CELL CARCINOMA
3.1. Pleomorphic adenoma
3.1.1. Definition
A benign neoplasm composed of ductal epithelial and myoepithelial cells set within a
mesenchymal stroma.
3.1.2. Immunohistochemical stains
Cytokeratin cocktail, S100 protein, SMA, p63, calponin, MSA, GFAP, and CD10 reactive the
cells are highlighted by a mixture of epithelial and myoepithelial markers that include AE1/
AE3, CK5/6, CK7, and CK14; S-100 protein; p63; SMA; calponin; and GFAP. (Figure 3). [14-16]
3.2. Basal cell adenoma
3.2.1. Definition
Basal cell adenoma is a benign salivary gland epithelial neoplasm composed of a proliferation
of small basaloid cells in solid, tubular, trabecular, or membranous patterns. (Figure 4).
3.2.2. Immunohistochemical stains
Immunohistochemical Inner luminal cells: cytokeratin cocktail, CK7, and CD117 Peripheral
basaloid cellS_100 protein, p63, SMA, and MSA [17 -19]
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a) 
 
b) 
 
Figure 4. a) Basal cell adenoma, trabecular type b) p63 highlights the basal cells
3.3. Canalicular adenoma
3.3.1. Definition
Canalicular adenoma is a benign epithelial salivary gland neoplasm characterized by chains
of columnar cells and preference for the minor salivary glands.
3.3.2. Immunohistochemical stains
Cytokeratin and S100 protein reactive GFAP is reactive at the tumor/connective tissue interface
(Figure 5.) [17-23].
3.4. Oncocytoma
3.4.1. Definition
Oncocytoma (oncocytic adenoma) is a putative neoplastic proliferation of oncocytically altered
cells.
a) b)
Figure 3. a) Pleomorphic adenoma shows a mixture of myoepithelial cells and isolated duct-tubular structures b) S-100
protein in the myoepithelial cells.
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3.4.2. Immunohistochemical stains)
Cytokeratin, p63, and PTAH reactive (Figure 6) [17- 19, 21, 22]
a) b)
Figure 6. a) Oncocytes are Cytokeratin, highly positive polygonal cells with abundant granular eosinophilic cytoplasm
and round, centrally placed nuclei, with or without nucleoli. b) p63 reactive.
3.5. Papillary cystadenoma lymphomatosum (Warthin’s tumor)
3.5.1. Definition
Warthin’s tumor is a relatively common lesion composed of a double layer of oncocytic and
cystic architectural pattern cells, and a dense lymphoid epithelium in a papillary stroma.
(Figure7)
3.5.2. Immunohistochemical stains
Epithelial component keratin reactive Lymphoid component reactive with B- and T-cell
markers [17- 19]
a)  b) 
 
Figure 5. a) Canalicular adenoma, b) GFAP staining is positive
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Figure 7. a) Papillary-cystic tumor associated with a dense lymphoid stroma. b) KI 67 positive B- cell component.
3.6. Sebaceous adenoma / lymphadenoma
3.6.1. Definition
Sebaceous adenoma is a benign epithelial neoplasm composed of proliferating, incompletely
differentiated sebaceous glands. Sebaceous lymph adenoma is a rare variant in which the
epithelial proliferation is supported by a dense lymphoid stroma and possibly arises from
entrapped salivary gland tissue within intraparotid or periparotid lymph nodes (Figure 8).
3.6.2. Immunohistochemical stains
Immunohistochemistry can be used to confirm the sebaceous differentiation (such as with
CD15, androgen receptor, or EMA Epithelial component is cytokeratin and is EMA reactive)
[17-19]
a)  b) 
 
Figure 8. a) Sebaceous lymphadenoma b) EMA highlights the sebocytes
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3.7. Mucoepidermoid carcinoma
3.7.1. Definition
A malignant glandular epithelial neoplasm characterized by mucus, intermediate, and
epidermoid cells. This common salivary gland malignancy represents between 2% and 16% of
all salivary gland tumors and up to one third of malignant salivary gland tumors.
3.8. Immunohistochemical stains
Intermediate and epidermoid cells are immunoreactive for cytokeratin and frequently EMA
Three cell populations can generally be seen in MEC- epidermoid cells, mucous cells, and
intermediate cells— variably set within a cystic background (Figure 9).
CK5/6, Ki-67, and p63 nuclear expression may help in the differential diagnosis. [23, 24]
a)  b) 
 
Figure 9. a) Mucoepidermoid carcinoma(H&E) and b) CK5/6 highlight the epidermoid and intermediate cells.
3.9. Adenoid cystic carcinoma
3.9.1. Definition
Adenoid cystic carcinoma accounts for 10% of all malignant salivary gland tumors. ACC is
cribriform and has two prominent growth patterns: Tubular, and solid, and it is composed of
epithelial and myoepithelial cells (Figure 10).
3.9.2. Immunohistochemical stains
Pseudocysts are positive for PAS, Alcian blue, laminin, and type IV collagen Epithelial cells
are positive for low-molecular-weight keratins, EMA, and CD117 Myoepithelial cells are
positive with calponin, SMA, S100 protein, and p63. [25 – 32].
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a)  b) 
 
Figure 10. a) Adenoid cystic carcinoma showing multiple patterns b) CD117 highlights the epithelial cells.
Polymorphous low-grade adenocarcinoma.
3.9.3. Definition
This is a malignant epithelial tumor characterized by an infiltrative growth of cytologically
uniform cells (“low-grade”) arranged in architecturally diverse patterns (polymorphous),
slowly growing tumor that exclusively affects the minor salivary glands, most often of the
palate (Figure 11).
3.9.4. Immunohistochemical stains
Cytokeratin, vimentin, and S100 protein are positive. Variable results are seen with immuno‐
histochemistry and are rarely of diagnostic value. It reacts with EMA, S-100 protein, and Bcl-2;
these findings can help differentiate it from PA and ACC. [17-19, 33]
 
a)  b) 
 
Figure 11. a) polymorphous low-grade adenocarcinoma b) S-100 protein
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3.10. Epithelial-myoepithelial carcinoma
3.10.1. Definition
Epithelial-myoepithelial carcinoma is a low-grade, malignant, biphasic salivary tumor that
comprises 1% to 2% of all salivary neoplasms, the majority of which develop in the parotid
gland. It is a malignant neoplasm with biphasic duct-like structures composed of an inner
layer of duct lining, epithelium-type cells and an outer layer of clear, myoepithelial-type
cells (Figure 12).
3.10.2. Immunohistochemical stains
Inner cells are positive for keratin; outer myoepithelial cells are calponin, SMA, p63, and, less
reliably, S100 protein positive; CD117 and bcl-2 are frequently positive. [17- 19, 34
 
a) 
 
b) 
 
Figure 12. a) Epithelial-myoepithelial carcinoma b) smooth muscle actin strongly stains the myoepithelial cells
3.11. Clear cell Carcinoma
3.11.1. Definition
Many salivary and nonsalivary tumors contain clear cells. Among these are mucoepidermoid
carcinoma, acinic cell carcinoma, oncocytoma, renal cell carcinoma, myoepithelioma, and clear
cell odontogenic carcinoma.
3.11.2. Immunohistochemical stains
The neoplastic cells are positive with AE1/AE3, CAM5. 2, CK7, EMA, and p63; cells are negative
with S-100 protein, calponin, actins, and GFAP (Figure 13). They are usually negative for
myoepithelial markers that include S-100 protein, MSA, SMA, SMMHC, calponin, and GFAP
and are also negative for CD10, CK20, vimentin, desmin, RCC, CA9, and Pax-2 see). [35-37]
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a)  b) 
 
Figure 13. a) Clear cell carcinoma b) Highlighted clear cells by S100
3.12. Acinic cell carcinoma
3.12.1. Definition
A malignant epithelial neoplasm demonstrating serous acinar cell differentiation with
cytoplasmic zymogen secretory granules (Figure 14).
3.12.2. Immunohistochemical stains
PAS-positive, diastase-resistant zymogen granules. Acinic cells may stain positively for
amylase, transferrin, lactoferrin, CEA, VIP, and others. About 10% show some positivity for
S100 protein. [38, 39]
Figure 14. a) Serous acinar cells have abundant pale to basophilic, heavily granular cytoplasm (H&E). b) Trypsin is
detectable in acinar cells.
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4. Soft tissue tumors
The most common soft tissue tumors needing IHC are:
• Lobular capillary hemangioma
• Fibrosarcoma
• Angiosarcoma
• Kaposi Sarcoma
• Leiomyosarcoma
• Synovial Sarcoma
• Rhabdomyosarcoma
• Granular Cell Tumor
4.1. Lobular capillary hemangioma
4.1.1. Definition
Lobular capillary hemangioma previously commonly referred to as “pyogenic granuloma, ”
is a reactive soft tissue growth with a predilection for the oral cavity that is histologically
characterized by a lobular arrangement (Figure15).
4.1.2. Immunohistochemical stains
Positive for endothelial markers including factor VIII–related antigen and CD31 of proliferat‐
ing small blood vessels. [17-19]
Figure 15. a) H&E capillary hemangioma b) CD31 highlights the endothelial cell C) Factor VIII noted in the endothelial
cells.
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4.2. Fibrosarcoma
4.2.1. Definition
Malignant neoplasm with only fibroblastic/myofibroblastic differentiation (Figure 16).
4.2.2. Immunohistochemical stains
Vimentin, and rarely, focal actin positivity. [40, 41]
Figure 16. a) Hypercellular tumor, showing spindle cells. b) Vimentin is highly positive
4.3. Angiosarcoma
4.3.1. Definition
Uncommon, high-grade malignant vascular neoplasm, occasionally associated with radiation.
4.3.2. Immunohistochemical stains
Positive with CD34, CD31, factor VIII–RAg, vimentin, podoplanin. ERG shows nuclear
positivity in nearly 100% of angiosarcomas. FLI1 expression is found in as many as 100% of
angiosarcomas, but utility is limited by poor specificity for vascular lesions. CD31 expression
is found in more than 90% of angiosarcomas (Figure 17).
VEGFR3 expression is found in approximately 50% of angiosarcomas, [42-50]
4.4. Kaposis sarcoma
4.4.1. Definition
Kaposi sarcoma is a malignant neoplasm of endothelial cells. Oral lesions are commonly
multifocal. Early lesions: are flat, red, and asymptomatic. Older lesions: larger, darker, nodular,
and ulcerated. KS is common in patients with AIDS.
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4.4.2. Immunohistochemical stains
Human herpes virus 8 has variable expression for endothelial markers (CD31, CD34)[17, 18,
19, 48, 51] (Figure 18).
 
a)  b) 
 
 
 
Figure 18. a) Nodular aggregates of spindle cells forming slit-like spaces (H&E). b) CD34 is positive.
4.5. Leiomyosarcoma
4.5.1. Definition
Malignant tumor of smooth muscle
4.5.2. Immunohistochemical stains
Currently, IHC confirmation of smooth muscle differentiation in LMS is based on the dem‐
onstration of desmin, α–SMA, muscle actin (HHF-35), and h-Caldesmon PAS with diastase
will highlight intracellular glycogen. Tumor cells will be strongly and diffusely reactive with
vimentin and actins (smooth muscle, muscle-specific), while variably positive for desmin [49,
50, 51, 52, 53, 54] (Figure 19) [52-57].
Figure 17. a) Richly vascularized tumor with open vascular channels and mitotic figures b) CD 31 is positive.
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Figure 19. a) Spindle cell population. b) Desmin reactivity.
4.6. Synovial sarcoma
4.6.1. Definition
Synovial sarcoma is a malignant soft tissue tumor that shows epithelial and mesenchymal
differentiation and has distinct clinical, genetic, and morphologic features.
Although it was once thought that synovial sarcoma arose in association with synovium, it is
now well known that this is not the case and that these tumors may arise at any anatomic
location.
4.6.2. Immunohistochemical stains
Morphologically, synovial sarcoma takes three main forms: 1) biphasic, 2) monophasic, and
3) poorly differentiated. Biphasic synovial sarcoma (BSS) consists of a fascicular spindle cell
component and an epithelial component that usually shows glandular differentiation, whereas
monophasic synovial sarcoma (MSS) lacks the epithelial component. The glandular compo‐
nent of synovial sarcoma expresses cytokeratins, including AE1/AE3. EMA expression is
typically observed in both BSS and MSS. however, unlike its biphasic counterpart, MSS tends
to be focally and inconsistently reactive for cytokeratins.
In particular, MSS may show reactivity for simple keratins: CK7, CK8, CK18, and CK19. S-100
protein expression is found in approximately 30% of synovial sarcomas. CD99 is commonly
observed in MSS, but expression of this marker is also shared by some other spindle cell
neoplasms. Strong positivity for BCL2 protein has also been noted in the spindle cell compo‐
nent of synovial sarcoma. [55-58]. TLE1 is positive in synovial sarcoma (Figure 20).
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Figure 20. a) Spindle or epithelioid cells show a predominantly nested growth pattern. b) TLE1 is positive
4.7. Rhabdomyosarcoma
4.7.1. Definition
A malignant neoplasm with skeletal muscle phenotype: Embryonal type (80%): Alveolar type
(20%)
4.7.2. Immunohistochemical stain
MYOD1, SMA positive A variety of myoid markers are positive (desmin, myogenin, MyoD1,
myoglobin, actins), but it is important to remember that AE1/AE3, CAM5. 2, and CD56, along
with synaptophysin, may be focally positive in some cases. [59, 60, 61] (Figure 21)
a) b)
Figure 21. a) Mesenchymal cells and rhabdomyoblasts b) Desmin
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4.8. Granular cell tumor
4.8.1. Definition
This is an uncommon tumor composed of poorly demarcated granular cells, thought to be
Schwann-cell derived, that frequently arise below a mucosa, the latter often showing pseu‐
doepitheliomatous hyperplasia. Granular cell tumor tends to affect the oral cavity (tongue
most commonly). Tumors are usually smooth surfaced, poorly demarcated, and are often
polypoid, and measure from1 to 2 cm.
4.8.2. Immunohistochemical stains
The neoplastic cells yield a strong and diffuse nuclear and cytoplasmic S-100 protein reaction
and are also positive for CD68, NSE, α-1–antitrypsin [17-19, 62] (Figure 22).
a) b)
Figure 22. a) Polygonal granular cells H&E b) neoplastic ells with s-100
5. Hematologic disorders
The common hematologic disorders that need IHC stains are;
• Hodgkin's lymphoma
• Non – Hodgkin's lymphoma
• Extranodal NK/T-Cell lymphoma, (angiocentric T-cell lymphoma) Midline lethal granulo‐
ma
• Burkitt's lymphoma
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5.1. Hodgkins lymphoma
This almost always begins in the lymph nodes, and any lymph node group is susceptible.
The most common sites of initial presentation are the cervical and supraclavicular nodes (70%
to 75%). Hodgkin's lymphoma is currently classified in the following manner:
• Lymphocyte-rich
• Nodular sclerosis
• Mixed cellularity
• Lymphocyte depletion
5.1.1. Immunohistochemical stains
The antibodies most commonly used for diagnosing HL are Ber-H2 (CD30), LeuM1 (CD15),
LCA (CD45), L26 (CD20), CD75 (LN1), CD74 (LN2), PAX5, CD3, UCHL1 (CD45RO), ALK,
fascin, and EBV-LMP1. EMA and CD57 can be used to recognize NLPHL.
Monoclonal antibody LN1 reacts with H/RSCs in approximately one third of HL cases, most
frequently in cases of NLPHL (>75% of cases)(Figure 23). [17-19]
Figure 23. a) Hodgkin/Reed-Sternberg cells b) antigenic Reed-Sternberg cells for CD15
5.2. Non- Hodgkins lymphoma
5.2.1. Definition
Non-Hodgkin's lymphoma most commonly develops in the lymph nodes, In the oral cavity.
Lymphoma usually appears as extranodal disease. The malignancy may develop in the oral
soft tissues or centrally within the jaws; they most commonly affect the buccal vestibule,
posterior hard palate, or gingiva.
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5.2.2. Immunohistochemical stains
Small Cell Lymphoid Neoplasms
The lymphoma cells express pan–B-cell antigens (CD19, CD20, CD22, PAX-5). Mantle cell
lymphoma (MCL) expresses pan–B-cell antigens (CD19, CD20, CD22), CD5, CD43, Bcl-2, and
cyclin D1.
Nodal marginal zone lymphoma (NMZL) will typically express pan–B-cell antigens that
include CD19, CD20, PAX5, and CD79a;
Co-expression with Bcl-2 and CD43 is common and occurs in 50%. The vast majority of low-
grade follicular lymphoma (FL) are positive for Bcl-2 small lymphocytic lymphoma (CLL/SLL)
includes expression of CD5, CD23, CD19, CD43, and Bcl-2 and has a proliferation rate of less
than 10%. [17-19] (Figure 24).
Large B-Cell Lymphoid Neoplasms
CD15 expression +
CD30 +
CD45 expression +
PAX5 strong, uniform + CD20 strong, uniform +.
CD79a expression +.
p63 +
a) b)
Figure 24. a) B-cell lymphoma (H&E) b) CD 20 is positive
T-Cell Lymphoid Neoplasms
Almost all peripheral T-cell lymphomas express pan–T-cell antigens CD3, CD2, and CD43.
Anaplastic large-cell lymphoma (ALCL) is positive for CD30, and the expression should be
strong and in at least 75% of the cells.
The neoplastic cells of angioimmunoblastic T-cell lymphoma)AITL) are positive for pan–T-cell
antigens CD3, CD2, CD5, [17-19]
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5.3. Extranodal NK/T-cell lymphoma, (angiocentric T-cell lymphoma) midline lethal
granuloma
5.3.1. Definition
NK/T-cell lymphoma is the most common malignant nonepithelial neoplasm found in the
upper respiratory tract and most commonly involves the nasal cavity, the maxillary sinus,
nasopharynx, and salivary gland. This discussion will be limited to extranodal NK/T-cell
lymphoma, nasal type (NK/T LNT), which is more common in the sinonasal region.
5.3.2. Immunohistochemical stains
NK cells express CD2, CD7, CD8, CD56, and CD57. They are positive for cytoplasmic CD3,
but not surface CD3, and do not typically express CD5. The neoplastic counterpart, extranodal
NK/T-cell lymphomas, express CD2, cytoplasmic CD3, CD56, and, in most cases, EBV. [17-19]
(Figure 25, 26).
Figure 25. a) Extranodal natural killer/T-cell lymphoma b) CD3 staining is positive
a) b)
Figure 26. a) Atypical lymphoid cells(NK/T-CELL LYMPHOMA) b) Diffusely immunoreactive with CD3C
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5.4. Burkitts lymphoma
5.4.1. Definition
Burkitt's lymphoma is a malignancy of B-lvmphocyte origin that represents an undifferenti‐
ated lymphoma. The tendency for jaw involvement seems to be age related: nearly 90% of 3-
year-old patients have jaw lesions.
5.4.2. Immunohistochemical stains
There were statistically significant differences in the expression of CD10 (28/28 vs. 1/16), bcl-2
(3/28 vs. 11/16), MUM1 (5/28 vs. 15/16), a PI of 95. 0% or more (27/28 vs. 2/16), and combined
CD10+/bcl-2-/bcl-6+ (24/28 vs. 1/16) between BLs and DLBCL-HPSSs. Of the BLs, 7 (25%) of 28
and 26 (96%) of 27 were positive for EBER and c-myc rearrangement as compared with 0 of 16
and 1 (7%) of 15 DLBCL-HPSSs, respectively as compared with 0 of 16 and 1 (7%) of 15 DLBCL-
HPSSs, respectively. [17-19, 63]
 
a)  b) 
 
 
 
Figure 27. a) Burkitt's lymphoma. "starry-sky" appearance b) CD10 staining
6. Bone tumors
The common bone tumors needing IHC are:
• Osteosarcoma
• Chondrosarcoma
• Ewing sarcoma
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6.1. Osteosarcoma
6.1.1. Definition
Osteosarcoma is the most common nonhematopoietic primary malignant bone tumor ; it is a
malignant mesenchymal tumor producing osteoid from the tumor cells (Figure 28).
6.1.2. Immunohistochemical stains
CD99 positive; rare cytokeratin and smooth muscle actin reaction. Overall, the reported
specificity of immunoreactivity for osteonectin and osteocalcin is approximately 40% and 95%,
respectively, for the diagnosis of a bone forming tumor. A recent promising marker for
identification of osteoblastic differentiation is SATB2, a nuclear matrix protein that plays a role
in osteoblast lineage commitment. α-SMA and desmin, which can lead to misdiagnosis. [63-69]
a) b)
Figure 28. a) Osteosarcoma demonstrates irregular trabeculae of tumor osteoid arising from sarcomatous stroma. b)
CD99 is positive
6.2. Chondrosarcoma
6.2.1. Definition
Chondrosarcoma is a malignant tumor of bone that shows pure cartilaginous differentiation.
Secondary changes that include myxoid features, ossification, and calcification may be present.
(Figure 29).
6.2.2. Immunohistochemical stains
Cartilage stains S100 protein positive Mesenchymal chondrosarcoma: Sox9, CD99, and Leu7
positive Although the cartilaginous component of mesenchymal chondrosarcoma is S-100
protein positive, the small-cell component expresses CD99, CD57, and NSE therefore immu‐
nohistochemically, there may also be overlap with Ewing sarcoma. However, unlike Ewing
sarcoma, MCS is nonreactive for synaptophysin and also typically does not express desmin,
actin, cytokeratin, or EMA. In addition, MCS lacks EWSR1 gene rearrangements. However, a
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recent study has identified a novel HEY1-NCOA2 fusion in MCS which appears to be a
consistent finding. [70, 71]
a) 
 
b) 
 
 
 
Figure 29. a) High-grade chondrosarcoma b) with marked S100 PROTEN increase in cellularity and myxoid matrix
6.3. Ewing sarcoma
6.3.1. Definition
High-grade, primitive neuroectodermal neoplasm (Figure 30)
6.3.2. Immunohistochemical stains
Positive: FLI1 (nuclear), CD99, vimentin; rarely keratin. May react with other neural markers
(NSE, synaptophysin, S100 protein, NFP, GFAP, chromogranin). [72-79]
a) b)
Figure 30. a) Small nucleoli scant cytoplasm with mitosis b) diffuse strong membranous expression of CD99
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